Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Non-Current Assets (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Other Non-Current Assets data on record, last reported at $5.6 million in Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 320.2% year-over-year to $5.6 million; the TTM value through Dec 2025 reached $5.6 million, up 320.2%, while the annual FY2025 figure was $5.6 million, 320.2% up from the prior year.
  • Other Non-Current Assets reached $5.6 million in Q4 2025 per APLS's latest filing, up from $5.5 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $5.6 million in Q4 2025 and bottomed at $898000.0 in Q2 2025.
  • Average Other Non-Current Assets over 5 years is $1.7 million, with a median of $1.3 million recorded in 2023.
  • The widest YoY moves for Other Non-Current Assets: up 320.2% in 2025, down 32.94% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $1.6 million in 2021, then decreased by 18.55% to $1.3 million in 2022, then dropped by 12.49% to $1.1 million in 2023, then grew by 18.67% to $1.3 million in 2024, then soared by 320.2% to $5.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $5.6 million in Q4 2025, $5.5 million in Q3 2025, and $898000.0 in Q2 2025.